Faris Farooq Saeed Khan

Faris Farooq Saeed Khan

Auto-generated profile, based on publicly available information

Faris Farooq Saeed Khan

Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
HBHumera Bukhari
Humera Bukhari
AAAneeqa Ahmad
Aneeqa Ahmad
ANAmna Noorin
Amna Noorin
AKAimal Khan
Aimal Khan
MMMehwish Mushtaq
Mehwish Mushtaq
FKFaris Farooq Saeed Khan
Faris Farooq Saeed Khan
End-stage renal disease (ESRD) patients are mostly managed with maintenance hemodialysis (MHD). ESRD patients on MHD also present with many complications, such as anemia, hyperparathyroidism, and hepatitis prevalence. This study depicts the real-world scenario of anemia among MHD and end-stage renal disease patients in the Pakistani population. A retrospective, multicentric, and real-world data analytical study was conducted at 4 dialysis centers in Pakistan. The study had a sample size of n = 342 patients on maintenance hemodialysis. The data were gathered from the medical records of patients. Data analysis was performed using STATA Version 16. Statistical significance was gauged at a 0.05 level of significance. According to our results, the mean age of the patients was 45 (±15) years. Most of the patients were male (n = 234, 68.4%), whereas 58.1% of the patients were maintained on twice-weekly hemodialysis. The most commonly reported comorbidities were hypertension and diabetes mellitus. The frequency of dialysis ( < 0.01) and comorbidities ( = 0.009) had a significant association with anemia in MHD patients. The majority of the patients had hyperparathyroidism (52%) with anemia. Upon performing binary logistic regression, multivariate analysis displayed a similar odds value for having anemia in patients with every additional month in the duration of hemodialysis (OR 1.01, = 0.001), the odds of anemic patients having a positive antihepatitis-C antibody (OR 2.22, = 0.013), and the odds of having anemia in patients in the age category below 45 years (OR 1.93, = 0.013). In conclusion, the study results depict that every additional month in the duration of hemodialysis, age (<45 years), and positive anti-HCV antibody status, these variables were more likely to have anemia in our study MHD patients. While in our final multivariate model, no statistically significant association was observed between hyperparathyroidism and anemia.